XENETIC BIOSCIENCES INC (XBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.86-7.21%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · XBIO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Xenetic’s DNase technology was built on the insight that NETs have been implicated in the context of cancer pathogenesis and resistance to cancer therapies and can form mechanical barriers that imped…
Stated in a supplied disclosure. Management reported: “Xenetic’s DNase technology was built on the insight that NETs have been implicated in the context of cancer pathogenesis and resistance to cancer therapies and can form mechanical barriers that impede T-cell penetration and occlude T-cell contact with tumor cells that can contribute to resistance to CAR-T therapy,” said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Stated in 2 of 2 supplied quarters. Management reported: “Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.” “Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.”
“Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.”
“Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.”
We believe this disciplined approach, combined with continued royalty revenue from our legacy PolyXen technology, positions Xenetic to pursue long-term opportunities that have the potential to create…
Stated in 2 of 2 supplied quarters. Management reported: “We believe this disciplined approach, combined with continued royalty revenue from our legacy PolyXen technology, positions Xenetic to pursue long-term opportunities that have the potential to create meaningful value for both patients and shareholders."” “The Company ended the first quarter of 2026 with approximately $7.3 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025.”
“We believe this disciplined approach, combined with continued royalty revenue from our legacy PolyXen technology, positions Xenetic to pursue long-term opportunities that have the potential to create…”
“Recent Highlights · Generated robust translational data supporting the DNase I platform across multiple oncology settings · Completed process improvement and analytical development activities support…”
Conduct strategic review process including potential transactions to enhance shareholder value and advance company strategy.
Over the trailing year it converted 1.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.